Clinical Trial: A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age

U.S., March 19 -- ClinicalTrials.gov registry received information related to the study (NCT07478952) titled 'A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age' on March 13.

Brief Summary: The main objective of this trial is to evaluate the safety and immunogenicity of mRNA-1189 after intradermal and intramuscular delivery.

Study Start Date: March 16

Study Type: INTERVENTIONAL

Condition: Epstein-Barr Virus

Intervention: BIOLOGICAL: mRNA-1189

Sterile liquid for injection

Recruitment Status: NOT_YET_RECRUITING

Sponsor: ModernaTX, Inc.

Published by HT Digital Content Services with permission from Health Daily Digest....